



ADULT MEDICATION GUIDELINE

URSODEOXYCHOLIC ACID (UDCA)

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

[Formulary: Restricted](#)

Medication Class

Gastrointestinal drug

Presentation

Tablet: 500mg

Capsule: 250mg

Oral liquid: 50mg/mL

Storage

Store at room temperature, below 25°C

Do not use Ursofalk Suspension after 4 months of opening the bottle

Dose

Obstetric cholestasis

Route: Oral

10-15mg/kg daily in 2 or 3 doses (usually 250-500mg 3 times each day). Adjust dose according to response.

Administration

Oral

Can be taken with or without food

Capsules can be opened and dispersed in water or mixed with yoghurt or apple puree

Monitoring

Liver function and bilirubin each month for first 3 months then every 3 months.

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Considered safe to use

3rd Trimester: Considered safe to use

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Considered safe to use

Comments

Obstetric cholestasis- non-PBS indication

Related Policies, Procedures & Guidelines



[Cholestasis in pregnancy](#)

References

Australian Medicines Handbook. Ursodeoxycholic acid. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Aug 25]. Available from: <https://amhonline.amh.net.au/>

MIMS Australia. Ursodeoxycholic acid GH. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 Aug 25]. Available from: <https://www.mimsonline.com.au>

The Royal Women's Hospital. Ursodeoxycholic acid. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2021 Aug 25]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Ursodeoxycholic acid, cholestasis, urso, UDCA, ursofalk, URAO, pruritis, obstetric cholestasis				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	Feb 2015	Last Reviewed:	Nov 2021	Review Date:	Nov 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	Jan 2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance				
	<input checked="" type="checkbox"/>  Std 4: Medication Safety				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.